# STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

> **NCT05519527** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Refractory T Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Part 1 (STI-6129)
- **DRUG:** Part 2 (STI-6129)

## Key facts

- **NCT ID:** NCT05519527
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08-16
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 patient accrual
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519527, "STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05519527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*